triptorelin (Trelstar) Report issue

Biologics Peptide Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It works by decreasing the production of certain hormones, which reduces testosterone levels in the body. Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone. Triptorelin is indicated for the palliative treatment of advanced prostate cancer.   NCATS

Chemistry

  • SMILES: CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H](Cc4c[nH]c5ccccc45)NC(=O)[C@H](Cc6c[nH]cn6)NC(=O)[C@@H]7CCC(=O)N7)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N8CCC[C@H]8C(=O)NCC(=O)N
  • InChIKey: VXKHXGOKWPXYNA-PGBVPBMZSA-N
  • Mol. Mass: 1311.47
  • ALogP: Missing data
  • ChEMBL Molecules:
    triptorelin  
    triptorelin pamoate  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$5.0195
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(6-d-tryptophan)luteinizing hormone-releasing hormone | arvekap | cl-118532 | decapeptyl | (d-trp6)-gnrh | gonapeptyl | luteinizing hormone-releasing factor (pig), 6-d-tryptophan | pglu-his-trp-ser-tyr-d-trp-leu-arg-pro-gly-nh2 | trelstar | trelstar depot | triptorelin | triptorelina | triptorelin acetate | triptoreline | triptorelin embonate | triptorelin pamoate | triptorelinum | tryptorelin

Organizations (218)

Research & Development (213)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (55)

Approved Indications (1)


 

Prostatic Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (55)


 

Adenomyosis (Phase 3)

Alkylating Agents (Phase 2/Phase 3)

Androgens (Phase 3)

Breast Neoplasms (Phase 3)

Castration (Phase 3)

Clomiphene (Phase 4)

Deficiency Diseases (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 2/Phase 3)

Embryo Transfer (Phase 4)

Endometrial Neoplasms (Phase 2)

Endometriosis (Phase 4)

Fatigue (Phase 3)

Fatty Liver (Phase 4)

Female Urogenital Diseases (Phase 2)

Fertility (Phase 4)

Fertility Preservation (Phase 2/Phase 3)

Fertilization in Vitro (Phase 4)

Gender Dysphoria (Phase 4)

Gonadal Disorders (Phase 1)

Gonadotropin-Releasing Hormone (Phase 4)

Growth and Development (Phase 4)

Healthy Volunteers (Phase 2/Phase 3)

HIV Infections (Phase 2)

Hormones (Phase 2)

Hyperprolactinemia (Phase 1)

Hypogonadism (Phase 4)

Infertility (Phase 4)

Infertility, Female (Phase 4)

Kallmann Syndrome (Phase 1)

Leukemia, Myeloid, Acute (Phase 3)

Lupus Erythematosus, Systemic (Phase 2)

Lymphoma (Phase 3)

Metabolic Syndrome (Phase 4)

Mifepristone (Early Phase 1)

Neoadjuvant Therapy (Phase 2/Phase 3)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2/Phase 3)

Osteoporosis (Phase 3)

Osteosarcoma (Phase 3)

Ovarian Diseases (Phase 3)

Ovarian Hyperstimulation Syndrome (Phase 4)

Ovarian Neoplasms (Phase 4)

Polycystic Ovary Syndrome (Phase 4)

Primary Ovarian Insufficiency (Phase 4)

Prostate (Phase 2)

Prostatic Neoplasms ()

Prostatic Neoplasms, Castration-Resistant (Phase 2/Phase 3)

Puberty, Precocious (Phase 4)

Salivary Gland Neoplasms (Phase 2)

Sarcoma (Phase 3)

Sarcoma, Ewing (Phase 3)

Sleep Wake Disorders (Phase 3)

Sperm Injections, Intracytoplasmic (Phase 4)

Tendon Injuries (Phase 4)

Uterine Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 185
  • # of Trial Organizations: 213

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue